Hansoh Pharmaceutical Group (HKG:3692) obtained clinical trial approval in China for HS-10529, according to a late Tuesday disclosure with the Hong Kong Exchange.
HS-10529 will be investigated as a treatment for advanced solid tumors, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer with KRAS G12D mutations.
The stock slipped over 2% in afternoon trade on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。